Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Emgality Versus Nurtec ODT Head-To-Head Migraine Preventive Treatment Study Now Enrolling Patients

11/18/2021 | 08:00am EST

Eli Lilly and Company announced that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head trial comparing two anti-calcitonin gene-related peptide (CGRP) medicines for the preventive treatment of episodic migraine in adults. The study is evaluating once-monthly Emgality (galcanezumab-gnlm) injection compared to Nurtec ODT (rimegepant), a tablet patients take every other day, on patient-centric measures, including reductions in monthly migraine headache days and quality of life improvement. While Nurtec ODT and Emgality are both medications that target CGRP, because Emgality is a?monoclonal antibody (mAb) that binds to CGRP (a protein found in the brain thought to play a key role in migraine), it works differently than gepants like Nurtec ODT, that bind to and block the CGRP receptor.?Emgality is the only CGRP medication with =50%, =75% and 100% reductions of monthly migraine headache days in its label for people with episodic migraine experiencing 4 to 14 migraine headache days per month. Lilly's CHALLENGE-MIG study aims to deepen the understanding of CGRP monoclonal antibodies (mAbs) compared to oral gepants in the preventive treatment of migraine and answer important questions that will help physicians and patients make informed treatment decisions. The CHALLENGE-MIG clinical trial is expected to enroll approximately 700 adults across the U.S. with episodic migraine, and individual participation in the study can last up to 6 months. For more information about the CHALLENGE-MIG trial, contact The Lilly Answers Center at 1-800-LillyRx (1-800-545-5979). Information about the CHALLENGE-MIG study is also available at the Lilly booth at the American Headache Society's annual education symposium taking place in Scottsdale, AZ, November 18-21, 2021.


ę S&P Capital IQ 2021
All news about ELI LILLY AND COMPANY
01/25GLOBAL MARKETS LIVE : Credit Suisse, Unilever, Nvidia, Tesla, American Express...
01/25WALL STREET STOCK EXCHANGE : A roller-coaster week as Fed decision looms
01/25MARKETSCREENER’S WORLD PRESS REVIEW : January 25, 2022
01/24US FDA Restricts Use of Eli Lilly, Regeneron's COVID-19 Treatments
MT
01/24FDA to Restrict Monoclonal Antibodies Manufactured by Eli Lilly, Regeneron Pharmaceutic..
MT
01/24Morgan Stanley Adjusts Eli Lilly and Co.'s Price Target to $272 from $275, Keeps Overwe..
MT
01/21Innovent and Eli Lilly and Company Announces Final Clinical Results and Biomarker Analy..
CI
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21Alzheimer's patient groups protest U.S. Medicare coverage proposal limiting use of new ..
RE
01/21DZ Bank Upgrades Eli Lilly and Co. to Buy From Hold; Price Target is $291
MT
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 28 205 M - -
Net income 2021 6 216 M - -
Net Debt 2021 12 037 M - -
P/E ratio 2021 37,0x
Yield 2021 1,40%
Capitalization 216 B 216 B -
EV / Sales 2021 8,07x
EV / Sales 2022 8,02x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 237,86 $
Average target price 285,18 $
Spread / Average Target 19,9%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY-13.89%215 642
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
NOVO NORDISK A/S-15.89%213 450